Provenance Record

Clear, well-structured News piece (913 words) using the Overview / What We Know / What We Don't Know / Analysis format. Technical clinical detail (dose-response, A1C thresholds, AHI, WOMAC) is presented accurately and accessibly. Every numeric claim carries an inline [according to ...] attribution to a specific source.

All 3 snapshots read from disk (none failed; status 200, no archive fallback). source-1.html.gz (PR Newswire, May 21 obesity topline): confirmed verbatim — TRIUMPH-1, 2,339 participants, 1:1:1:1, the full dose-response (4 mg 47.2 lbs/19.0%; 9 mg 64.4 lbs/25.9%; 12 mg 70.3 lbs/28.3%; placebo 5.5 lbs/2.2%), the 104-week BMI>=35 extension (85.0 lbs/30.3%), 45.3% achieving >=30% weight loss ('a level long associated with bariatric surgery'), 65.3% reaching BMI<30, the 2 mg step-wise dose-escalation quote, all 12 mg AEs (nausea 42.4 vs 14.8, diarrhea 32.0 vs 13.5, constipation 26.1 vs 10.9, vomiting 25.3 vs 4.8), 11.3% vs 4.9% discontinuation, and the Jastreboff lead-investigator quote with correct Yale title. source-0.html.gz (PR Newswire, June 6 ADA release): confirmed verbatim — A1C up to 2.0% from baseline 7.9%, up to 90% below 7.0%, up to 46% below 5.7% (normoglycemia), diabetes 12 mg weight loss 36.6 lbs/16.8% at 40 weeks, WOMAC knee-pain up to 4.3 points/73.1% from baseline 6.0, AHI up to 36.1 events/hr/60.6% from baseline 58.6, and the second Jastreboff '200 downstream diseases' quote. source-2.html.gz (BioSpace): confirmed verbatim — June 6 / Ernest N. Morial Convention Center / New Orleans, 537 participants over 40 weeks, simultaneous Lancet publication, 'first triple-hormone therapy', the safety statement ('similar to those of GLP-1 receptor agonists already in use, with no new reported safety concerns'), and the Bajaj quote attributed to 'Harpreet Singh Bajaj, MD, MPH, lead author of the study'.

No fabricated or misattributed clinical statistic found. Rule 9 (clinical scrutiny) satisfied: every clinical specific traces to an accessible snapshot. The TRANSCEND-T2D-1 Lancet paper is referenced ONLY as a fact-of-publication, sourced to BioSpace/Lilly — no specific is drawn from the (inaccessible) Lancet DOI, which is not in the source array. The diabetes complications figures (A1C, WOMAC, AHI) are correctly cited to the June 6 Lilly release (source-0), not the Lancet. Both Jastreboff quotes are attributed to Jastreboff (source-0/source-1) and the Bajaj quote to Bajaj (source-2) — no speaker cross-attribution. No tirzepatide head-to-head comparison or '532'-style alternate cohort figure appears in the body.

High-quality, fully sourced clinical News submission. Signature and payload hash valid; bidirectional source coverage intact (3 body URLs == 3 source-array URLs, no orphans). Every clinical number, dose, adverse-event rate, and direct quote verified verbatim against the correct snapshot. Approved for publication as-is.